Division of GlaxoSmithKline PLC
Latest From SmithKline Beecham
Reps. Welch and Rooney urge FTC and DOJ to condition their approval of the merger on inclusion of a pricing provision.
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.
€24m loan from the European Investment Bank with match funding will progress Phase IIb antifungal Olorofim in invasive aspergillosis. CFO Ralf Schmid goes into details with Scrip.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Jean-Pierre Garnier, CEO
John Coombe, CFO
James Niedel, MD, PhD, CSO & CTO
Tadataka Yamada, MD, Chmn., R&D
Russell Greig, SVP, Global Bus. Dev.
Robert Ingram, Pres. & COO, Pharm. Oper.
- Contact Info
Phone: (215) 751-4000
One Franklin Plaza
P.O. Box 7929 Philadelphia, PA 19101-
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.